Equillium (EQ) Stock Price, News & Analysis

Company Overview

Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company’s research is based on modulating immune pathways involved in T-cell activation, inflammation and tissue damage.

Its lead investigational product is itolizumab, an anti-CD6 monoclonal antibody designed to regulate pathogenic T-cell activity. Equillium has evaluated itolizumab in immune-mediated conditions, including acute graft-versus-host disease and other inflammatory disorders. The company has also pursued additional antibody-based programs aimed at treating serious diseases driven by abnormal immune responses.

Equillium is headquartered in San Diego, California, and has collaborated with Biocon Limited, which discovered itolizumab. Through this relationship, Equillium has held development and commercialization rights for selected markets outside Biocon’s core territories. The company was co-founded by Krishna Polu, who has served as its chief executive officer.

Key Stats

• Today's Range: $1.65 to $1.74
• 50-Day Range: $1.75 to $2.76
• 52-Week Range: $0.76 to $3.54
• Volume: 73,595 shs
• Average Volume: 614,222 shs
• Market Capitalization: $107.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.57
• Consensus Rating: Moderate Buy

Equillium Stock Analysis - MarketRank™

Equillium scored higher than 46% of companies evaluated by MarketBeat, and ranked 560th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Equillium has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Equillium has a consensus price target of $7.57, representing about 344.9% upside from its current price of $1.70.

Amount of Analyst Coverage

Equillium has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Equillium are expected to decrease in the coming year, from ($0.21) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Equillium is -8.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Equillium is -8.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Equillium has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.31% of the float of Equillium has been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Equillium has recently decreased by 2.96%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Equillium does not currently pay a dividend.

Dividend Growth

Equillium does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.28

News Sentiment

Equillium has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Equillium this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for EQ on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Equillium to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Equillium insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.84% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

27.05% of the stock of Equillium is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EQ
• CIK: 1746466
• Web: equilliumbio.com
• Phone: (858) 412-5302
• Fax: N/A
• Employees: 14
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Equillium: $7.57
• High Price Target: $12.00
• Low Price Target: $5.00
• Potential Upside/Downside: +346.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.40 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.15%
• Return on Assets: -38.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 23.40
• Quick Ratio: 23.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.47 per share
• Price / Book: 3.61

Miscellaneous

• Outstanding Shares: 63,408,000
• Free Float: 52,096,000
• Market Cap: $107.48 million
• Optionable: Not Optionable
• Beta: 1.81